United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

British American Tobacco

Kinder Morgan

Main Street Capital

AT&T

Whirlpool

A financial advisor can help you understand the advantages and disadvantages of investment properties.

6 Absolutely Best Dividend Stocks Yielding Over 6%

Structure Therapeutics Inc

Novo Nordisk

Viking Therapeutics

Contenders are beginning to emerge from the lab, some with the potential to unseat Lilly's Zepbound and Novo's Wegovy.

Wegovy and Zepbound Are King. Who's Coming for Their Crowns.

Best Buy

Kohl's

Sabra Health Care

TC Energy

The company offers medicines and vaccines in various therapeutic areas, including: Cardiovascular metabolic and women's health under the Premarin family and Eliquis brands Biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands Sterile injectable and anti-infective medicines and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

6 Bargain Dividend Stocks To Buy

Canadian Pacific Kansas City Limited

Extra Space Storage

Raytheon Technologies

Market sentiment is bullish but not at extreme levels, suggesting unusual developments in market sentiment, with surprisingly loose financial conditions.

Beware Of Low Returns! Here Are 4 Dividend Stocks With Over 12% Annual Return Potential

Pfizer's stock has plummeted by nearly 55% from its all-time high, but it remains a solid company with potential for considerable upside. Technical indicators suggest that Pfizer's stock has likely found a bottom and could begin a new long-term uptrend.

Pfizer: A Strong Buy Trading Below A 10 P/E Ratio

Pfizer's stock is still reeling from the decline of its coronavirus-related sales. At least one Wall Street analyst thinks that it has a bright future.

1 Wall Street Analyst Thinks Pfizer Stock Is Going to $45. Is It a Buy Around $26?

Altria

SL Green Realty

Cohen & Steers Infrastructure Fund Inc

Verizon

The markets had a good week, with the S&P 500 increasing by 0.84% and the Dow Jones jumping 1.59%.

Dividend Harvesting Portfolio Week 157: $15,700 Allocated, $1,389.49 In Projected Dividends

Bristol-Myers

Disney

Intel

PayPal

If you're searching for must-have stocks for wealth, look no further. In investing, identifying the right stocks leads to a fear of missing out.

Millionaire's Blueprint: 7 Must-Have Stocks for Your Road to Wealthy Town

Anheuser-Busch InBev

Estee Lauder

JD.com

Polaris

Sensata Technologies Hld

Yum China Hlds

The stock market keeps hitting new record highs almost every week. With sectors like semiconductors and AI taking off, the sky is the limit.

Strong Buy Alert: Analysts Say to Scoop Up These 7 Stocks

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public listen to a webcast of a discussion with Mikael Dolsten, Chief Scientific Officer & President, Pfizer Research and Development, at the Leerink Partners Global Biopharma Conference 2024 on Tuesday, March 12, 2024 at 8:00 a.m. Eastern Daylight Time. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.

Pfizer - Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer Inc. (NYSE:PFE ) TD Cowen 44th Annual Health Care Conference March 4, 2024 11:10 AM ET Company Participants David Denton - Chief Financial Officer and Executive Vice President Conference Call Participants Steve Scala - TD Cowen Steve Scala Well, good morning once again. We're delighted to have Pfizer here at Cowen's 44th Annual Healthcare Conference.

Pfizer Inc. (PFE) TD Cowen 44th Annual Health Care Conference

The market valuation has become lofty, boosted by 2021-like buying behavior and a surge in growth/tech stocks. In this environment, value stocks have become very attractive, potentially allowing investors to generate above-average returns in the years ahead. Pfizer has become one of my favorite value plays, as it benefits from a promising pipeline, a well-covered dividend, an increasingly healthy balance sheet, and a very cheap valuation.

6%-Yielding Pfizer Is An Ultra-Deep-Value Gem In An Expensive Market

This stock has plunged in recent years mainly because of declining demand for two of its key products. However, it's poised to return to growth, is dirt cheap, and pays an especially juicy dividend.

1 S&P 500 Dividend Stock Down 56% to Buy and Hold Forever

Annaly Capital

Over the past half-century, dividend-paying companies have run circles around nonpayers in the return department. Although higher-yield stocks come with added risk, proper research can uncover some amazing deals.

3 Magnificent Ultra-High-Yield Dividend Stocks That Are Screaming Buys in March

Casella Waste Systems

Dollar General

EZCORP

NextEra Energy

Newmont Mining

Sempra Energy

With rising jitters tied to broader monetary policy and its impact on the equities sector, stocks to buy for a market downturn has spiked in interest. Nevertheless, it pays to plan ahead with ideas that might ride out the red ink.

Plan Ahead! 7 Stocks to Buy Before Any Market Downturn Occurs

Barrick Gold

Lockheed Martin

The S&P 500 has been trending higher by 7% in the first two months of 2024. While sentiments seem positive, the markets need to navigate blowing macroeconomic headwinds.

3 Volatility-Busting, Low-Beta Stocks to Grab Now

The fading interest in combating COVID-19 has taken a toll on Pfizer's top and bottom lines. Pfizer stock has risen and fallen with its coronavirus business, but the pullback has been exaggerated.

1 Magnificent S&P 500 Dividend Stock Down 56% to Buy and Hold Forever

Bank of America

The fourth quarter (Q4) shined bright for hedge funds, marking it a standout period in the investment realm. According to a recent report released by a U.K.-based data investment business, global hedge fund returns surged 7.1% in Q4, pushing returns to 13.3% for 2023, after a slight drop of 0.1% in the third quarter (Q3).

Hot on the Hedge Funds' Trail: 3 Stocks Worth Your Bet?

Seagen

Pharma giant Pfizer, fresh off its $43 billion acquisition of Seagen, said it will shut down construction on a new 270,000 square-foot manufacturing facility Seagen was building north of Seattle near its headquarters.

Pfizer to close Seagen manufacturing plant in Seattle area following $43B acquisition

News for Pfizer Stock (PFE)